| Protocol |
Title |
Status |
Contact |
| 103434 |
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Therapies Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin (LOTIS-7) |
OPEN TO ACCRUAL |
 |
| 103164 |
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies |
OPEN TO ACCRUAL |
|
| 103588 |
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors |
OPEN TO ACCRUAL |
|
| 103371 |
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma |
OPEN TO ACCRUAL |
|
| 103579 |
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma |
OPEN TO ACCRUAL |
|
| 103428 |
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma |
OPEN TO ACCRUAL |
|
| 103469 |
Multi-Center, Open-Label, Single-Arm Phase I Dose-Escalation and Phase II Dose-Expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-Tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 |
OPEN TO ACCRUAL |
|
| 103374 |
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b |
OPEN TO ACCRUAL |
|
| 103596 |
Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) |
OPEN TO ACCRUAL |
|
| 103389 |
Phase 3 Trial Using the SYK Inhibitor, Entospletinib, in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed, NPM1-mutated Acute Myelogenous Leukemia |
OPEN TO ACCRUAL |
|
| 103435 |
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
OPEN TO ACCRUAL |
|
| 103408 |
A Phase 1B Trial of Tarloxotinib and Sotorasib in Patients with KRAS G12C Mutations |
OPEN TO ACCRUAL |
|
| 103352 |
Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, a Phase I/II Trial |
OPEN TO ACCRUAL |
|
| 103396 |
A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumors |
OPEN TO ACCRUAL |
|
| 103446 |
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201) |
OPEN TO ACCRUAL |
|
| 103438 |
A Phase 1b/2, Randomized, Study of AVB-S6-500 in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Advanced Clear Cell Renal Cell Carcinoma Who Have Received Front-Line Treatment |
OPEN TO ACCRUAL |
|
| 103401 |
A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer |
OPEN TO ACCRUAL |
|
| 103421 |
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination With CX-072 in Advanced Triple-Negative Breast Cancer |
OPEN TO ACCRUAL |
|
| 103465 |
A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) in Patients With Advanced Solid Tumors
|
OPEN TO ACCRUAL |
|
| 103390 |
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD1/L1, EGFR, Or ALK Inhibitor |
OPEN TO ACCRUAL |
|